Enhertu: Data from P3 DESTINY-Breast11 trial (NCT05113251) for HER2+ neoadjuvant breast cancer in 2025 (AstraZeneca) - Feb 8, 2024 - Q4 & FY2023 Results: Data from P1b/2 DESTINY-Breast07 trial (NCT04538742) for HER2+ve metastatic breast cancer in 2025
P1/2 data • P3 data • Breast Cancer • HER2 Positive Breast Cancer • Oncology
|